2-chloro-N-[5-[5-(2-fluorophenyl)-2-methylpyrazol-3-yl]-1,3-thiazol-2-yl]benzamide | 1361379-73-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-chloro-N-[5-[5-(2-fluorophenyl)-2-methylpyrazol-3-yl]-1,3-thiazol-2-yl]benzamide
• CAS: 1361379-73-8
• 化学式: C₂₀H₁₄ClFN₄OS
• 分子量: 412.875
• InChiKey: AEYLQNRHBCLWPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  88
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM
  申请人：Whitten Jeffrey P.

  公开号：US20120053210A1

  公开（公告）日：2012-03-01

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.

  本文描述了含有这些化合物的化合物和药物组合物，这些化合物调节储存操作钙（SOC）通道的活性。本文还描述了使用这种SOC通道调节剂的方法，单独或与其他化合物结合，用于治疗需要抑制SOC通道活性的疾病或症状。
• Compounds that modulate intracellular calcium
  申请人：CalciMedica Inc.

  公开号：US10336738B2

  公开（公告）日：2019-07-02

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.

  本文描述了调节储存操作钙（SOC）通道活性的化合物和含有此类化合物的药物组合物。本文还描述了使用此类 SOC 通道调节剂（单独使用或与其他化合物结合使用）治疗可从抑制 SOC 通道活性中获益的疾病或病症的方法。
• US9079891B2
  申请人：——

  公开号：US9079891B2

  公开（公告）日：2015-07-14
• [EN] COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM<br/>[FR] COMPOSÉS MODULANT LE CALCIUM INTRACELLULAIRE
  申请人：CALCIMEDICA INC

  公开号：WO2012027710A2

  公开（公告）日：2012-03-01

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store- operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.